Echosens and Boehringer Ingelheim have expanded their long-standing partnership to change the trajectory of metabolic dysfunction-associated steatohepatitis (MASH) by moving beyond clinical trials to focus on early detection, diagnosis, and access to care. In combining diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps in awareness, real-world evidence, and clinical adoption. The next phase of the partnership will raise awareness of MA...